OBM Transplantation (ISSN 2577-5820) is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc., which covers all evidence-based scientific studies related to transplantation, including: transplantation procedures and the maintenance of transplanted tissues or organs; assimilation of grafted tissue and the reconstitution of removed organs or parts of organs; transplantation of heart, lung, kidney, liver, pancreatic islets and bone marrow, etc. Areas related to clinical and experimental transplantation are also of interest.
OBM Transplantation is committed to rapid review and publication, and we aim at serving the international transplant community with high accessibility as well as relevant and high quality content.
The journal publishes all types of articles in English. There is no restriction on the length of the papers. We encourage authors to be concise but present their results in as much detail as necessary, as reviewers are expected to emphasize scientific rigor and reproducibility.
Publication Speed (median values for papers published in 2023): Submission to First Decision: 6.7 weeks; Submission to Acceptance: 14.4 weeks; Acceptance to Publication: 6 days (1-2 days of FREE language polishing included)
Topical Collection
Advances in Lung Transplant
Editor
Shambhu Aryal, MD,FCCP
Inova Advanced Lung Disease an Lung Transplant Program, Inova Fairfax Medical Campus, 3300 Gallows Road, Falls Church, VA 22042, USA
Website | E-Mail
Research Interests: Lung Transplantation; Interstitial Lung Disease; Sarcoidosis; Pulmonary Hypertension; Cystic Fibrosis
Topical Collection Information
Lung transplantation is an established life-saving treatment for select patients who have failed conventional conservative medical therapy for their lung disease. After the first successful surgery in the early 1980s, the number of lung transplantations performed worldwide has increased steadily to about 5000 transplants per year. This increase in numbers has enriched the experience of the lung transplant community and led to several advances in the field. Improvement in surgical techniques and peri-operative management in the first couple of decades of lung transplantation led to improvement in early post-transplant survival. More recently, a lot of interest and resources are being put into important areas including primary graft dysfunction, organ preservation and rehabilitation, biomarkers in lung transplantation, antibody mediated rejection, and chronic lung allograft dysfunction. These works are expected to significantly improve both short-term and long-term outcomes including survival and quality of life for lung transplant recipient.
The collection will provide a forum for presenting current research works and clinical results showing advancement in the field of lung transplantation noted above. The collection will also be open to any author. Each submission will be reviewed by at least two reviewers to ensure a very high quality of papers selected for the collection.
Keywords:
Lung transplantation; Acute cellular rejection; Antibody mediated rejection; Primary graft dysfunction; Donor derived cell-free DNA; Biomarkers for lung transplantation; Chronic lung allograft dysfunction; Bronchiolitis obliterans syndrome; Restrictive allograft syndrome; Extracorporeal photopheresis
Publication (9 papers)
Open Access
Original Research
by
Michael Y. Shino
, Francisco Javier Ibarrondo
, Jesse L. Clark
, Adreanne Rivera
, Marlene Florian
, Allison Ramsey
, Ariss Derhovanessian
, Rajan Saggar
, Olawale O. Amubieya
, Grant Turner
, Joanna M. Schaenman
, Pryce T. Gaynor
, Omer E. Beaird
, Ashrit Multani
, Reshma M. Biniwale
, Murray H. Kwon
, Christos J. Petropoulos
, Yolanda Lie
, Terri Wrin
, Amparo L. Figueroa
, Brett Leav
, Zelalem Endale
, Kate Anteyi
, Jacqueline M. Miller
, Abbas Ardehali
, David M. Sayah
, David Elashoff
, John A. Belperio
, Otto O. Yang
and
S. Sam Weigt
Abstract
Higher-dose mRNA booster vaccines have not been well studied for transplant recipients. This study evaluated the safety, reactogenicity and immunogenicity of higher dose mRNA-1273 booster vaccines among lung transplant recipients (LTRs). This phase 1/2 open-label randomized clinical trial of higher- [...] |
Abstract
Lung transplantation in patients with end stage lung disease can improve survival and quality of life. Airway complication incidence varies between 2-33%, but the true incidence is difficult to determine due to a lack of validated classification systems. There are many risk factors for post lung tra [...] |
Abstract
Chronic allograft dysfunction (CLAD) is one of the leading causes of death after lung transplantation [1]. CLAD is a progressive and irreversible decline in lung function after transplant, manifested as an obstructive, restrictive, or mixed ventilatory impairment without any identifiable [...] |
Abstract
The shortage of donor lungs for transplantation is a major challenge, resulting in longer waitlist times for patients with a higher risk of waitlist mortality. It is crucial to continue promoting awareness about organ donation through legislation, public campaigns, and health care provider education [...] |
Abstract
Lung transplantation is a last-resort treatment option for patients with end stage lung disease. The procedure is being performed more frequently and scientific advances continue to be made, but the median post-transplant survival is far shorter than other solid organ transplant recipients. Candidat [...] |
Open Access
Original Research
Abstract
In the United States of America, COVID-19 acute respiratory distress syndrome (ARDS) and post-COVID pulmonary fibrosis (PCPF) are raising indications for lung transplant (LT). Another indication for LT is underlying fibrosis with SARS-CoV-2 induced interstitial lung disease exacerbation or rapid pro [...] |
Abstract
Advances in the use of molecular biomarkers to guide management of lung transplant recipients are emerging. One such biomarker, donor-derived cell-free DNA (dd-cfDNA), has the potential to alter traditional approaches of lung transplant management, including the detection of acute reject [...] |
Abstract
A boundless spectrum of chronic lung diseases is said to effect over 500 million persons globally. Lung transplantation is a well-established therapeutic option for patients suffering from end-stage lung diseases, however waitlist mortality and primary graft failure remain major determinants as post [...] |
Abstract
Few reports have described successful lung transplantation from a donor with a history of SARS-CoV-2 infection, and outcomes beyond 3 to 6 months remain unknown. After weighing the urgency and life-saving benefits of lung transplantation against the risk of viral transmission, we successfully perfor [...] |